- Featured
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, 12-AVR-131, or **17-AVP-786-305.** Participants will be enrolled in the study for approximately 56 weeks (participants who have a follow-up visit 3 months after the last dose of treatment will be enrolled for approximately 64 weeks). Approximately 1200 participants will be enrolled at approximately 250 centers globally. All participants enrolled will receive AVP-786; the treatment dose assigned will be masked to the participant, investigator, study staff, and the sponsor.
Phase
3Span
500 weeksSponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Ormond Beach, Florida
Recruiting
- Featured
Pelle-926-203 Study, a research study for adults 18 years of age and older with High Frequency Basal Cell Carcinoma.
The purpose of the study is to determine the safety and effectiveness of an investigational topical gel for the reduction of facial Basal Cell Carcinomas requiring surgery in people living with HF-BCC.
Phase
2Span
Sponsor
Ormond Beach, Florida
Recruiting